Filtered By:
Condition: Hypertension
Countries: USA Health
This page shows you your search results in order of date. This is page number 15.
Order by Relevance | Date
Total 432 results found since Jan 2013.
Social Vulnerability and Premature Cardiovascular Mortality Among US Counties, 2014 to 2018
CONCLUSIONS: In this analysis, US counties with more social vulnerabilities had higher premature CVD mortality, varied by demographic characteristics and rurality. Focused public health interventions should address the socioeconomic disparities faced by underserved communities to curb the growing burden of premature CVD.PMID:34662161 | DOI:10.1161/CIRCULATIONAHA.121.054516
Source: Circulation - October 18, 2021 Category: Cardiology Authors: Safi U Khan Zulqarnain Javed Ahmad N Lone Sourbha S Dani Zahir Amin Sadeer G Al-Kindi Salim S Virani Garima Sharma Ron Blankstein Michael J Blaha Miguel Cainzos-Achirica Khurram Nasir Source Type: research
Measuring the COVID-19 Mortality Burden in the United States : A Microsimulation Study
CONCLUSION: Beyond excess deaths alone, the COVID-19 pandemic imposed a greater life expectancy burden on persons aged 25 to 64 years, including those with average or above-average life expectancies, and a disproportionate burden on Black and Hispanic communities.PRIMARY FUNDING SOURCE: National Institute on Aging.PMID:34543588 | DOI:10.7326/M21-2239
Source: Annals of Internal Medicine - September 20, 2021 Category: Internal Medicine Authors: Julian Reif Hanke Heun-Johnson Bryan Tysinger Darius Lakdawalla Source Type: research
Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Trends in Meeting the Aerobic Physical Activity Guideline Among Adults With and Without Select Chronic Health Conditions, United States, 1998-2018
CONCLUSIONS: Although rising trends in physical activity levels among adults with chronic health conditions are encouraging for improving chronic disease management, current prevalence remains low, particularly among older adults. Increasing physical activity should remain a priority for chronic disease management and control.PMID:34465653 | DOI:10.1123/jpah.2021-0178
Source: Journal of Physical Activity and Health - September 1, 2021 Category: Sports Medicine Authors: John D Omura Eric T Hyde Giuseppina Imperatore Fleetwood Loustalot Louise Murphy Mary Puckett Kathleen B Watson Susan A Carlson Source Type: research
Identification of Novel Gene Signatures using Next-Generation Sequencing Data from COVID-19 Infection Models: Focus on Neuro-COVID and Potential Therapeutics
In conclusion, our study unravels a rapid approach for applying next-generation knowledge discovery (NGKD) platforms to discover small molecules with therapeutic potential against COVID-19 and its related disease pathologies.
Source: Frontiers in Pharmacology - August 31, 2021 Category: Drugs & Pharmacology Source Type: research
Meta-Analysis Addressing the Effect of Mineralcorticoid Receptor Antagonists on the Risk for New-Onset Atrial Fibrillation
Atrial fibrillation (AF) constitutes the most common, major cardiac arrhythmia worldwide, with an estimated prevalence in the United States equal to 2.3 million affected subjects, projected to increase to 5.6 million by 2050.1 Hypertension and background heart disease (mainly, congestive heart failure) or valve disease represent main risk factors for AF development.1 Other modifiable risk factors are sedentary lifestyle, smoking, obesity, diabetes mellitus, and obstructive sleep apnea.2 AF is associated with a significant increase in the risk for all-cause and cardiovascular death, ischemic stroke, heart failure (HF), isch...
Source: The American Journal of Cardiology - August 13, 2021 Category: Cardiology Authors: Dimitrios Patoulias, Christodoulos Papadopoulos, Maria Toumpourleka, Michael Doumas Source Type: research
Cardiovascular health status of taxi/for-hire vehicle drivers in the United States: A systematic review
CONCLUSIONS: Rigorous and high quality research is needed to further investigate rates of cardiovascular health in this population. The complexity of data collection in this group presents challenges to this endeavor. The high prevalence of poor nutrition, limited physical activity, diabetes, and blood pressure across studies indicates an urgent need to address low rates of health care access at a policy level and to design targeted workplace interventions.PMID:34219688 | DOI:10.3233/WOR-213525
Source: Work - July 5, 2021 Category: Occupational Health Authors: Sheena Mirpuri Kathryn Traub Sara Romero Marisol Hernandez Francesca Gany Source Type: research
